Testing safety and effects of antibodies in infants exposed to HIV-1
Official title: OPEN-LABEL PHASE I STUDY OF THE SAFETY AND PHARMACOKINETICS OF NEUTRALIZING MONOCLONAL ANTIBODIES IN INFANTS EXPOSED TO HIV-I
Funded at Westat, INC. · NIH-11181769 · Data updated 2026-11-12
This study is looking at how safe and effective a new treatment with special antibodies is for infants who have been exposed to HIV-1, and it's designed to help find better ways to prevent and treat HIV in young kids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Westat, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2024 |
| Award (this year) | $2,505,456 |
| NIH project number | 75N94023D00001-0-759402400001-1 |
| Project ID | NIH-11181769 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants who have been exposed to HIV-1, particularly those under the age of 12 months.
✕Less likely to help
Patients who are not infants or those who have not been exposed to HIV-1 may not benefit from this research.
What this research studies
This research investigates the safety and pharmacokinetics of neutralizing monoclonal antibodies in infants who have been exposed to HIV-1. The study is part of a larger effort by the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) to evaluate potential therapies for HIV in young populations. Participants will be monitored closely to assess how well their bodies process these antibodies and to ensure their safety during the treatment. The research aims to improve prevention and treatment strategies for HIV in infants and children.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for infants exposed to HIV-1.
How similar studies have gone: Previous research has shown promise in using monoclonal antibodies for treating HIV, indicating a potential for success in this approach.
Where this research is happening
-
Westat, INC.
Rockville, United States Active
Researchers
- Principal investigator: Driver, Barbara — Westat, INC.
- Study coordinator: Driver, Barbara
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding how broadly neutralizing antibodies may help HIV cure trials
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.